EU Health Care Monitoring Plan

28 October 1996

Italian Member of the European Parliament Danielo Poggiolini has launched a series of recommendations in the European Parliament for a European Union health care monitoring program. His report on amended proposals for the program's second reading contains a polemic against what he calls "the will of the Council of Ministers to empty Article 129 of the Rome Treaty of any substance."

Mr Poggiolini says the foot-dragging of EU Ministers is preventing the development of an EU public health policy. "The governments of the member states are suffering from a disquieting myopia," he adds. Concern for a community health policy would serve the European public interest and equally respond to members states' worries over their health budgets. Mr Poggiolini concedes that all EU states face severe health care cost problems, but the operation of the proposed EU health surveillance system would generate data enabling governments to establish priorities and improve efficiency.

He says the budgetary allocation for development of the project is "insulting;" Ministers failed to accept a proposal for a budget of 20 million Ecus ($25 million) and the allocation finally agreed was 13 million Ecus ($16.2 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight